What is the Tesamorelin + Ipamorelin stack? Tesamorelin + Ipamorelin is a two-peptide combination consisting of tesamorelin, a growth-hormone-releasing hormone (GHRH) analogue, and ipamorelin, a growth-hormone secretagogue acting at the ghrelin receptor. The pairing is encountered in commercial and research-oriented peptide markets, but it is not a standardized, FDA-approved combination formulation and has not been established as a clinically validated combination therapy.
Human combination evidenceNo dedicated controlled study identified
Individual-component evidenceSubstantially different between the two components
Regulatory statusTesamorelin: approved for a specific indication; Ipamorelin: not FDA-approved
Last reviewedSeptember 11, 2026
```
```
Figure 1 — The stack contains two distinct peptide components. Evidence for either component must not be interpreted as evidence that the combination itself is effective or safe.Figure 2 — Multi-component concentration is calculated independently for every ingredient. The total mass must not be substituted for each component's individual mass.
```
Tesamorelin + Ipamorelin BAC Water & Concentration Reference
For a multi-component vial, every peptide shares the same final liquid volume, but each retains its own mass. Therefore, each concentration is calculated separately. For example, a hypothetical vial containing 10 mg tesamorelin + 2 mg ipamorelin has 10 mg of tesamorelin and 2 mg of ipamorelin regardless of whether the mathematical final volume is 1 mL, 2 mL, 3 mL or 5 mL.
Tesamorelin concentration = tesamorelin mass ÷ final liquid volume
Ipamorelin concentration = ipamorelin mass ÷ final liquid volume
These are mathematical examples only. They do not establish a recommended reconstitution volume, dose, administration schedule, or treatment protocol.
Need to Calculate Another Vial or BAC-Water Volume?
```
The BacScience Universal BAC Water Calculator is primarily designed around single-compound concentration mathematics. For a multi-component blend, calculate each component separately using its own mass while keeping the final liquid volume constant.
Tesamorelin + Ipamorelin is a combination of two different growth-hormone-axis peptides. Tesamorelin is a GHRH analogue, whereas ipamorelin is a growth hormone secretagogue acting through the ghrelin/GHS-R1a pathway. The biological rationale for putting the two together is mechanistic, but that rationale is not equivalent to clinical evidence for the specific combination.
The two molecules should therefore be treated as separate research subjects when evaluating evidence. Tesamorelin has substantially more mature human clinical evidence because it underwent randomized trials and received FDA approval for a narrow indication. Ipamorelin has human research history but did not establish an approved therapeutic indication.
Important distinction: a commercially available vial containing two peptides is not automatically a clinically validated fixed-dose combination. The composition, ratio, purity specifications, excipients, container closure and intended use may vary between suppliers.
What's in Tesamorelin + Ipamorelin?
```
Tesamorelin
Human clinical evidence: substantial
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Its established clinical development has focused particularly on HIV-associated lipodystrophy and excess visceral abdominal adiposity.
Randomized studies have demonstrated reductions in visceral adipose tissue in the studied HIV-associated population. These results belong to tesamorelin monotherapy and should not be transferred to a tesamorelin + ipamorelin blend.
Ipamorelin
Human evidence: limited / indication-specific research
Ipamorelin is a synthetic peptide growth-hormone secretagogue associated with activation of the ghrelin receptor (GHS-R1a). Human pharmacokinetic and pharmacodynamic research has documented GH stimulation.
A randomized phase 2 study investigated intravenous ipamorelin for postoperative ileus. The study did not demonstrate a statistically significant difference in its key efficacy endpoint compared with placebo.
```
Why Are These Compounds Combined in Research or Market Practice?
The combination is generally based on the idea that the two peptides influence different parts of the growth-hormone signaling system. That is a pharmacological rationale, not proof that the specific tesamorelin + ipamorelin combination produces a superior clinical outcome.
```
01 — GHRH pathway
Tesamorelin is a GHRH analogue and acts through the GHRH receptor.
Component mechanism
02 — Secretagogue pathway
Ipamorelin is a growth-hormone secretagogue associated with the ghrelin/GHS-R1a receptor pathway.
Component mechanism
03 — Combination question
Whether these exact two molecules produce a clinically meaningful combined effect has not been established.
Unanswered
```
Evidence for Tesamorelin
Tesamorelin has randomized, placebo-controlled human evidence showing reductions in visceral adipose tissue in adults with HIV-associated abdominal fat accumulation. This evidence supports the individual component in its studied population—not the combination with ipamorelin.
Phase 3 evidence: A pooled analysis of two multicenter phase 3 trials included 806 antiretroviral-treated adults with HIV and excess abdominal fat. Tesamorelin treatment was associated with a significant reduction in visceral adipose tissue compared with placebo.
Randomized clinical evidence: Other randomized studies evaluated visceral fat and liver fat in antiretroviral-treated adults with HIV-associated abdominal adiposity.
Regulatory evidence: FDA labeling identifies tesamorelin as a GHRF analogue indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label does not establish the use of tesamorelin together with ipamorelin.
Evidence for Ipamorelin
Ipamorelin has human pharmacology and clinical research data, but it does not have the same regulatory or clinical-evidence status as tesamorelin. Human studies have examined GH release and other investigational applications, including postoperative ileus.
Human pharmacology: A human volunteer study characterized ipamorelin pharmacokinetics and pharmacodynamics and observed a dose-related GH response after intravenous administration.
Phase 2 clinical research: A randomized, double-blind, placebo-controlled study examined ipamorelin in postoperative ileus after bowel resection. The principal efficacy endpoint did not differ significantly from placebo.
Regulatory caution: Ipamorelin is not an FDA-approved drug. FDA materials have also discussed concerns involving compounded ipamorelin acetate, including potential immunogenicity and peptide-related impurities. A substance appearing in an FDA chemical identity database does not itself mean that the substance is FDA-approved.
Has the Complete Tesamorelin + Ipamorelin Combination Been Clinically Studied?
No dedicated controlled human clinical study establishing the tesamorelin + ipamorelin combination was identified in the literature reviewed for this page. Consequently, there is no clinical evidence establishing the safety, efficacy, optimal ratio, or clinical superiority of this specific combination.
```
01
Tesamorelin alone
Extensive human clinical research and FDA-approved indication.
02
Ipamorelin alone
Human research exists, but no FDA-approved therapeutic indication.
03
Both together
No dedicated clinical evidence establishing the combination.
04
Fixed formulation
No universally standardized tesamorelin:ipamorelin blend ratio.
```
Do not extrapolate: evidence that tesamorelin works in a particular clinical population does not demonstrate that adding ipamorelin improves the result. Likewise, evidence that ipamorelin can stimulate GH does not establish that adding it to tesamorelin improves clinical outcomes.
Common Tesamorelin + Ipamorelin Formulations
There is no single universally accepted formulation for tesamorelin + ipamorelin. Current commercial listings demonstrate that the mass ratio can vary substantially, which means the concentration of each component depends on the exact label of the vial.
Example formulation
Tesamorelin
Ipamorelin
Mass ratio
Status
8 mg blend
6 mg
2 mg
3 : 1
Commercial example; not a clinical standard
12 mg blend
10 mg
2 mg
5 : 1
Commercial example; not a clinical standard
15 mg blend
10 mg
5 mg
2 : 1
Commercial example; not a clinical standard
Commercial formulations can change. Always treat the actual vial label, certificate of analysis and manufacturer documentation as the source of composition for a specific research material.
The important mathematical rule for a two-component vial is simple: divide the mass of each component by the same final liquid volume. Do not add the two peptide masses together and then assign that total concentration to each ingredient.
Worked example: 10 mg Tesamorelin + 2 mg Ipamorelin
Total material = 12 mg Tesamorelin = 10 mg Ipamorelin = 2 mg
At 3 mL final volume: Tesamorelin = 10 ÷ 3 = 3.333 mg/mL Ipamorelin = 2 ÷ 3 = 0.667 mg/mL
Notice that 12 mg ÷ 3 mL = 4 mg/mL represents the combined mass concentration of both peptides. It does not mean that tesamorelin is 4 mg/mL or that ipamorelin is 4 mg/mL.
Correct multi-component logic: Component A concentration = Component A mass ÷ final volume. Component B concentration = Component B mass ÷ final volume.
How BAC-Water Volume Changes Every Component's Concentration
Final volume
Tesamorelin
Tesamorelin concentration
Ipamorelin
Ipamorelin concentration
1 mL
10 mg
10 mg/mL
2 mg
2 mg/mL
2 mL
10 mg
5 mg/mL
2 mg
1 mg/mL
3 mL
10 mg
3.333 mg/mL
2 mg
0.667 mg/mL
5 mL
10 mg
2 mg/mL
2 mg
0.4 mg/mL
Important: The table above is concentration mathematics, not a recommendation for how much liquid should be added to a particular vial. The appropriate diluent, volume, preparation method, storage conditions and route of administration depend on the specific product and its validated labeling or laboratory protocol.
BAC Water vs. Approved Tesamorelin Diluent
BacScience's mathematical calculator should not be confused with the approved product instructions for tesamorelin. For example, the FDA label for EGRIFTA SV specifies its supplied diluent and a particular single-dose vial formulation. That labeling does not establish bacteriostatic water as an interchangeable diluent for an arbitrary tesamorelin + ipamorelin blend.
This distinction is particularly important for research pages because a mathematical concentration calculation does not establish chemical compatibility, stability, sterility, preservative suitability, container compatibility or clinical appropriateness.
Formulation Comparison
Question
Tesamorelin
Ipamorelin
Combination
Scientific identity
GHRH analogue
Growth-hormone secretagogue
Two-component blend
Human research
Extensive
Limited / investigational
No dedicated combination evidence identified
FDA-approved component?
Yes, for a specific indication
No
No
Standardized blend ratio?
Not applicable
Not applicable
No
Combination efficacy demonstrated?
No
Research Limitations
```
Combination evidence gap
There is no established clinical evidence demonstrating that tesamorelin + ipamorelin is more effective or safer than either component alone.
Formulation variability
Commercially encountered ratios vary. A page describing one ratio must not imply that every vial uses the same composition.
Different evidence levels
Tesamorelin's evidence base is considerably stronger than ipamorelin's. The two components should not receive the same evidence rating.
Stability uncertainty
Concentration calculations do not establish peptide stability, aggregation behavior, sterility or shelf life after reconstitution.
```
Regulatory & Safety Considerations
Tesamorelin: FDA-approved tesamorelin labeling is specific to its approved formulation, population and indication. The label includes important warnings and precautions, including elevated IGF-1, fluid retention, glucose-related considerations and malignancy-related concerns.
Ipamorelin: Ipamorelin is not an FDA-approved drug. FDA has identified concerns regarding compounded ipamorelin acetate, including potential immunogenicity, aggregation and peptide-related impurities.
Combination: There is no FDA-approved tesamorelin + ipamorelin fixed-dose combination. A commercially packaged blend should therefore not be represented as an approved or clinically validated combination therapy.
This page is an educational scientific reference and concentration-math resource. It is not medical advice, a prescription, or a recommendation for human or veterinary administration.
Frequently Asked Questions
```
What is Tesamorelin + Ipamorelin?
It is a two-component peptide combination containing tesamorelin and ipamorelin. Tesamorelin is a GHRH analogue, while ipamorelin is a growth hormone secretagogue.
Is Tesamorelin + Ipamorelin an FDA-approved combination?
No. Tesamorelin has an FDA-approved product for a specific indication, but the tesamorelin + ipamorelin combination itself is not an FDA-approved fixed-dose combination.
Has Tesamorelin + Ipamorelin been clinically studied together?
No dedicated controlled clinical study establishing the efficacy or safety of the exact combination was identified for this review.
Is there a standard Tesamorelin-to-Ipamorelin ratio?
No universally standardized ratio was identified. Commercial examples vary, including 6 mg + 2 mg, 10 mg + 2 mg and 10 mg + 5 mg formulations.
How is concentration calculated for a two-peptide vial?
Divide the mass of each peptide separately by the final liquid volume. The same final volume is used for both calculations, but each peptide retains its own mass.
If a vial contains 10 mg tesamorelin and 2 mg ipamorelin, is the concentration 12 mg/mL?
Only if the final volume is exactly 1 mL—and even then, 12 mg/mL is the combined mass concentration. The individual concentrations would be 10 mg/mL tesamorelin and 2 mg/mL ipamorelin.
How much BAC water should be used for Tesamorelin + Ipamorelin?
There is no universal volume that can be presented as a clinically validated answer for an arbitrary two-peptide blend. The concentration depends mathematically on the exact component masses and final volume. Product-specific diluent instructions should not be replaced by a generic calculator.
Does evidence for tesamorelin prove that the combination works?
No. Tesamorelin's individual clinical evidence cannot be used as evidence that adding ipamorelin improves efficacy or safety.
Does evidence for ipamorelin prove that the combination works?
No. Ipamorelin's individual pharmacology and human research do not establish efficacy or safety for a tesamorelin + ipamorelin combination.
```
Related BacScience Research Resources
```
BAC Water Calculator
Calculate single-compound concentration mathematically and use multi-component logic when a vial contains more than one peptide.
FDA. EGRIFTA SV (tesamorelin) Prescribing Information. Initial U.S. approval 2010. Current labeling should be checked through FDA Drugs@FDA for the latest approved version.
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357:2359–2370. DOI: 10.1056/NEJMoa072375.
Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4291–4304. DOI: 10.1210/jc.2010-0490.
Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. DOI: 10.1001/jama.2014.8334.
Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014. DOI: 10.1007/s00384-014-2030-8.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. PMID: 10496658.
FDA Pharmacy Compounding Advisory Committee materials concerning ipamorelin / ipamorelin acetate, including characterization and safety considerations.
```
Last Reviewed: September 11, 2026 Evidence and regulatory information should be periodically rechecked as new studies, product labels and regulatory decisions become available.
Choosing a selection results in a full page refresh.
